Overview

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
Phase:
Phase 2
Details
Lead Sponsor:
University of Florida
Collaborator:
Novartis Pharmaceuticals
Treatments:
4'-N-benzoylstaurosporine
Cytarabine
Midostaurin
Staurosporine